By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – IntegenX today announced it has raised $40 million in a Series C financing round for the further development of its product pipeline and commercialization of its RapidHIT 200 Human Identification System.

Leading the round was new investor Essex Woodlands, a healthcare growth equity and venture capital firm. Existing investors Domain Associates, QuestMark Partners, Greenspring Associates, Cross Creek Capital, RONAholdings, Samsung Ventures, and strategic partner In-Q-Tel also participated in the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.